| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
cKGA (IC50 = 1 mM)
|
|---|---|
| ln Vitro |
Diazooxonorleucine shows a dose-dependent statistically positive increase in structural aberrations at 4 and 20 hours without S9 and at 4 hours with S9, according to the results of the in vitro chromosome aberration assay.
|
| ln Vivo |
Diazooxonorleucine is assessed for its in vivo clastogenic activity by looking for micronuclei in polychromatic erythrocyte (PCE) cells in bone marrow taken from male mice given intravenous doses of 500, 100, 10, 1, and 0.1 mg/kg one day and 48 hours later. Following a dose of 500, 100, and 10 mg/kg for 24 and 48 hours, the in vivo micronucleus assay shows a statistically significant response for micronucleus formation.[2]
|
| Cell Assay |
CHO cells are subjected to both the vehicle and nine different dose levels of the test article, which range from 0.1712 to 1712 μg/mL when an S9 reaction mixture is present or not.
|
| Animal Protocol |
6-week-old male ICR mice
500 mg/kg, 100 mg/kg, 10 mg/kg, 1 mg/kg, 0.1 mg/kg IV |
| References |
| Molecular Formula |
C6H9N3O3
|
|---|---|
| Molecular Weight |
171.15
|
| Exact Mass |
171.0644
|
| Elemental Analysis |
C, 42.11; H, 5.30; N, 24.55; O, 28.04
|
| CAS # |
157-03-9
|
| Related CAS # |
157-03-9;
|
| Appearance |
Solid powder
|
| SMILES |
C(CC(=O)C=[N+]=[N-])[C@@H](C(=O)O)N
|
| InChi Key |
YCWQAMGASJSUIP-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C6H9N3O3/c7-5(6(11)12)2-1-4(10)3-9-8/h3,5H,1-2,7H2,(H,11,12)/t5-/m0/s1
|
| Chemical Name |
(2S)-2-amino-6-diazo-5-oxohexanoic acid
|
| Synonyms |
Diazooxonorleucine; BRN 1725815; BRN1725815; BRN-1725815; NSC-7365; NSC7365; NSC 7365; DON
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~34 mg/mL (~198.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8428 mL | 29.2141 mL | 58.4283 mL | |
| 5 mM | 1.1686 mL | 5.8428 mL | 11.6857 mL | |
| 10 mM | 0.5843 mL | 2.9214 mL | 5.8428 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05478720 | Recruiting | Drug: 6-diazo-5-oxo-L-norleucine (DON) Drug: Placebo |
Malaria, Cerebral | Douglas Postels, MD, MS | August 16, 2022 | Phase 1 Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
